AU2016264137B2 - Contraceptive compositions and methods for improved efficacy and modulation of side effects - Google Patents

Contraceptive compositions and methods for improved efficacy and modulation of side effects Download PDF

Info

Publication number
AU2016264137B2
AU2016264137B2 AU2016264137A AU2016264137A AU2016264137B2 AU 2016264137 B2 AU2016264137 B2 AU 2016264137B2 AU 2016264137 A AU2016264137 A AU 2016264137A AU 2016264137 A AU2016264137 A AU 2016264137A AU 2016264137 B2 AU2016264137 B2 AU 2016264137B2
Authority
AU
Australia
Prior art keywords
progestin
shbg
estrogen
ligand
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016264137A
Other languages
English (en)
Other versions
AU2016264137A1 (en
Inventor
Michael E. Kafrissen
Agis Kydonieus
Katie MACFARLANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agile Therapeutics Inc
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of AU2016264137A1 publication Critical patent/AU2016264137A1/en
Application granted granted Critical
Publication of AU2016264137B2 publication Critical patent/AU2016264137B2/en
Priority to AU2021262853A priority Critical patent/AU2021262853B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016264137A 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects Active AU2016264137B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021262853A AU2021262853B2 (en) 2015-05-18 2021-11-08 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163113P 2015-05-18 2015-05-18
US62/163,113 2015-05-18
US201562254999P 2015-11-13 2015-11-13
US62/254,999 2015-11-13
PCT/US2016/033024 WO2016187269A1 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021262853A Division AU2021262853B2 (en) 2015-05-18 2021-11-08 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Publications (2)

Publication Number Publication Date
AU2016264137A1 AU2016264137A1 (en) 2018-01-18
AU2016264137B2 true AU2016264137B2 (en) 2021-08-19

Family

ID=56116539

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016264137A Active AU2016264137B2 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects
AU2021262853A Active AU2021262853B2 (en) 2015-05-18 2021-11-08 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021262853A Active AU2021262853B2 (en) 2015-05-18 2021-11-08 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Country Status (10)

Country Link
US (3) US20180125860A1 (https=)
EP (1) EP3297634A1 (https=)
JP (2) JP2018515552A (https=)
CN (1) CN107995864A (https=)
AU (2) AU2016264137B2 (https=)
BR (1) BR112017024783A2 (https=)
CA (1) CA2986039A1 (https=)
HK (1) HK1251938A1 (https=)
MX (1) MX2017014768A (https=)
WO (1) WO2016187269A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200129524A1 (en) * 2017-03-15 2020-04-30 Agile Therapeutics, Inc. Personalized contraceptive formulations
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253607A1 (en) * 1986-07-15 1988-01-20 American Home Products Corporation Combination dosage form for premenopausal women
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE19739916A1 (de) * 1997-09-11 1999-03-18 Hesch Rolf Dieter Prof Dr Med Mittel zur hormonalen Kontrazeption
EP0911029A2 (en) * 1997-06-23 1999-04-28 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
WO2000024384A1 (en) * 1998-10-23 2000-05-04 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin
US20040053901A1 (en) * 1999-11-24 2004-03-18 Te-Yen Chien Transdermal hormone delivery system: compositions and methods
WO2005092346A1 (en) * 2004-03-26 2005-10-06 Dong, Kejuan Using combination of estrogen and progestin with ultra low dose for long term oral contraception
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
BR0015802B1 (pt) * 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
JP4965263B2 (ja) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
CA2704117C (en) 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
ES2734510T3 (es) * 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
CA2740004A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198919B2 (en) * 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
EP2806862A2 (en) 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
EA030797B1 (ru) * 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
EP0253607A1 (en) * 1986-07-15 1988-01-20 American Home Products Corporation Combination dosage form for premenopausal women
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
EP0911029A2 (en) * 1997-06-23 1999-04-28 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916A1 (de) * 1997-09-11 1999-03-18 Hesch Rolf Dieter Prof Dr Med Mittel zur hormonalen Kontrazeption
WO2000024384A1 (en) * 1998-10-23 2000-05-04 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin
US20040053901A1 (en) * 1999-11-24 2004-03-18 Te-Yen Chien Transdermal hormone delivery system: compositions and methods
WO2005092346A1 (en) * 2004-03-26 2005-10-06 Dong, Kejuan Using combination of estrogen and progestin with ultra low dose for long term oral contraception

Also Published As

Publication number Publication date
HK1251938A1 (zh) 2019-05-03
US20240156838A1 (en) 2024-05-16
AU2021262853B2 (en) 2024-05-09
CN107995864A (zh) 2018-05-04
CA2986039A1 (en) 2016-11-24
JP2021169503A (ja) 2021-10-28
US20250319102A1 (en) 2025-10-16
AU2021262853A1 (en) 2021-12-02
EP3297634A1 (en) 2018-03-28
BR112017024783A2 (pt) 2018-08-07
JP2018515552A (ja) 2018-06-14
WO2016187269A1 (en) 2016-11-24
MX2017014768A (es) 2018-03-23
AU2016264137A1 (en) 2018-01-18
US20180125860A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
AU2021262853B2 (en) Contraceptive compositions and methods for improved efficacy and modulation of side effects
Abrams et al. Pharmacokinetic overview of Ortho Evra™/Evra™
US12390476B2 (en) Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
RU2122854C1 (ru) Комбинированный препарат для контрацепции, фармацевтическая упаковка для контрацепции
MXPA01009813A (es) Terapia interrumpida de reemplazo de hormonas con dosis bajas de estrogeno.
JP2018515552A5 (https=)
WO1993021926A1 (en) Minimizing progestin associated breakthrough bleeding
WO2002094281A1 (en) Means and method for hormonal contraception
Sicat Ortho Evra, a new contraceptive patch
JP2023156451A (ja) 個別化避妊製剤
RU2796919C2 (ru) Композиции для персонализированной контрацепции
HK40022808A (en) Personalized contraceptive formulations
CA2581932A1 (en) A method of female contraception and a kit for use therein
MXPA06004547A (en) Graduated estrogen contraceptive

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)